memo-inOncology – SPECIAL ISSUE

Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.

The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.

Congress reports


Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.


    ESMO Solid Tumours 2020 English

    memo – inOncology SPECIAL ISSUE

    Congress Report virtual ESMO 2020 Solid Tumors

    A GLOBAL CONGRESS DIGEST ON SOLID TUMORS Report from the ESMO Congress, 19th – 21st September 2020, virtual congress

    ESMO 2020 Lung Cancer English

    memo – inOncology SPECIAL ISSUE

    Congress Report virtual ESMO 2020 Lung Cancer

    This report summarizes a selection of abstracts presented at ESMO 2020 Lung Cancer.

    Now available!



    All videointerviews from virtual ASH 2020

    Steven P. Treon explains about innovative approaches in the treatment of Waldenström’s macroglobulinemia, future aspects and the successful use of BTK inhibition within niche groups of patients with WM, and potential benefits of BTK inhibitors regarding COVID-19 complications.

    Jorge Castillo relates to recent developments with respect to follicular lymphoma, multiple myeloma and Waldenström’s macroglobulinemia, current insights into CAR-T cell therapy in the setting of multiple myeloma, and the future of anti-CD38 antibody treatment in patients with WM.

    Alessandra Tedeschi summarizes the results from the MAGNOLIA and iNNOVATE trials, relates to recent advances in the management of marginal zone lymphoma and discusses the effect of the introduction of BTK inhibition on the prognosis of patients with Waldenström’s macroglobulinemia.

    Stephen Opat discusses the requirements for treatment-free long-term remission in the setting of CLL and talks about the future of BTK inhibitors and promising combinations in B cell malignancies in general, as well as the strengths and limitations of immune checkpoint inhibitors.